Wedbush Reiterates Outperform Rating for Aimmune Therapeutics (AIMT)

Wedbush reissued their outperform rating on shares of Aimmune Therapeutics (NASDAQ:AIMT) in a research report released on Monday.

Several other equities research analysts have also recently weighed in on AIMT. BidaskClub upgraded Aimmune Therapeutics from a sell rating to a hold rating in a report on Thursday, February 8th. Royal Bank of Canada began coverage on Aimmune Therapeutics in a report on Wednesday, February 7th. They issued an outperform rating and a $55.00 target price for the company. Zacks Investment Research upgraded Aimmune Therapeutics from a sell rating to a hold rating in a report on Monday, October 16th. ValuEngine cut Aimmune Therapeutics from a hold rating to a sell rating in a report on Friday, December 1st. Finally, Robert W. Baird began coverage on Aimmune Therapeutics in a report on Wednesday, December 20th. They issued an outperform rating and a $64.00 target price for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $57.25.

Aimmune Therapeutics (NASDAQ AIMT) opened at $37.84 on Monday. The company has a market capitalization of $1,975.03, a price-to-earnings ratio of -16.10 and a beta of -0.82. Aimmune Therapeutics has a 12-month low of $15.97 and a 12-month high of $40.65.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.09. equities analysts predict that Aimmune Therapeutics will post -2.51 earnings per share for the current year.

In related news, insider Susan E. Barrowcliffe sold 75,000 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $37.14, for a total transaction of $2,785,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Douglas T. Sheehy sold 1,648 shares of the company’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $37.33, for a total value of $61,519.84. Following the sale, the insider now owns 1,648 shares of the company’s stock, valued at $61,519.84. The disclosure for this sale can be found here. Insiders have sold a total of 134,294 shares of company stock valued at $5,097,144 over the last 90 days. 17.59% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of AIMT. Carillon Tower Advisers Inc. purchased a new stake in shares of Aimmune Therapeutics during the 4th quarter worth $58,838,000. Alliancebernstein L.P. lifted its stake in shares of Aimmune Therapeutics by 109.5% during the 4th quarter. Alliancebernstein L.P. now owns 1,400,281 shares of the biotechnology company’s stock worth $52,959,000 after purchasing an additional 731,927 shares during the last quarter. Citadel Advisors LLC lifted its stake in shares of Aimmune Therapeutics by 3,092.5% during the 3rd quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock worth $13,873,000 after purchasing an additional 542,111 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Aimmune Therapeutics by 12.6% during the 2nd quarter. Vanguard Group Inc. now owns 2,476,836 shares of the biotechnology company’s stock worth $50,923,000 after purchasing an additional 276,978 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of Aimmune Therapeutics by 26.6% during the 2nd quarter. State Street Corp now owns 1,087,320 shares of the biotechnology company’s stock worth $22,351,000 after purchasing an additional 228,429 shares during the last quarter. Hedge funds and other institutional investors own 73.14% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Wedbush Reiterates Outperform Rating for Aimmune Therapeutics (AIMT)” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.com-unik.info/2018/02/14/wedbush-reiterates-outperform-rating-for-aimmune-therapeutics-aimt.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit